Melanoma is one of the deadliest forms of skin cancer. Although BRAF inhibitors significantly enhance survival of metastatic melanoma patients, most patients relapse after less than a year of treatment. We previously reported that mRNA binding protein Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is overexpressed in metastatic melanoma and that expression of IGF2BP1 confers resistance to chemotherapeutic agents. Here we demonstrate that IGF2BP1 plays an important role in the sensitivity of melanoma to targeted therapy. Inhibition of IGF2BP1 enhances the effects of BRAF-inhibitor and BRAF-MEK inhibitors in BRAF V600E melanoma. Also, knockdown of IGF2BP1 alone is sufficient to reduce tumorigenic characteristics in vemurafenib-resistant melanoma. These findings suggest that IGF2BP1 can be a novel therapeutic target for melanoma.
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| INTRODUCTION
Melanoma accounts for a majority of deaths from skin cancers.
Although early stage melanomas are usually curable, the survival rate of patients with metastatic melanoma is significantly diminished.
Aberrant MAPK activation is commonly found in melanoma due to missense mutations of BRAF, especially BRAF V600E as the most common type of mutation. 1 Vemurafenib is an inhibitor of BRAF V600E and its administration significantly increased overall and progressionfree survival of melanoma patients. 2 However, most patients relapsed after 6 months of treatment and became resistant to second-line therapy. 3 While the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib significantly improved overall survival compared with vemurafenib monotherapy in previously untreated patients with metastatic melanoma with BRAF V600E or V600 K mutations, median progression-free survival is still less than 1 year. 4 Acquired resistance to BRAF inhibitors is caused by a variety of alterations in the MAPK and other signaling pathways, [5] [6] [7] [8] [9] and targeting all possible mechanisms to overcome resistance becomes a daunting challenge. Therefore, identification of a novel target that affects pro-survival and drug resistance pathways is needed to overcome acquired resistance.
IGF2BP1 is a multifunctional RNA-binding protein. Its overexpression in metastatic melanoma affects a variety of protooncogenes and oncogenic signaling pathways leading to tumor progression, survival, and resistance to chemotherapy. [10] [11] [12] In this report, we describe the role of IGF2BP1 in the sensitivity of melanoma to selective BRAF V600E inhibitors.
| RESULTS AND DISCUSSION
In our experiments, IGF2BP1 inhibition using shRNA specific to IGF2BP1 (shIGF2BP1) significantly reduced growth of melanoma cells Dual inhibition of BRAF and MEK, represented by dabrafenib and trametinib, respectively, increases the efficacy over single treatment, but resistance to combination therapy still arises. 13 We wanted to test 
| Colony formation assay
Cells were cotransfected with shScram. and pTK-puro plasmid or shIGF2BP1 and pTK-puro plasmid. 24 hrs after transfection, 5 × 10 5 cells were seeded in six-well plates in triplicates and was treated with puromycin (skmel2: 1 µg/mL; skmel28: 1 µg/mL, 451 Lu: 1 µg/mL, A375: 2 µg/mL, G361: 1 µg/mL, MRA5: 0.2 µg/ mL, MRA6: 0.3 µg/mL), and vemurafenib, dabrafenib, trametinib or dabrafenib + trametinib. Drug treatment with puromycin was maintained for 2-3 weeks until colonies become visible to the naked eye.
Colonies were fixed with 10% formalin for 1 h followed by staining with 1% crystal violet (w/v) in 1:1 ratio of water and methanol for 1 h.
| Cell growth assay (MTS assay)
Cells were counted using Countess II FL automated cell counter 
| Cell proliferation analysis
The same method as apoptosis assay was used until vemurafenib 
| Cell cycle analysis
| Statistical analysis
Because the data represents discrete events, we considered colony count data to have a Poisson distribution. We examined the colony count data with negative binomial regression models, because of their ability to handle overdispersion, and underdispersion well. For each model, the factors IGF2BP1 inhibition and vemurafenib dose level were tested for an interaction. In the presence of an interaction,
differences from 0 μM were tested within the Control and IGF2BP1 inhibition groups; Bonferroni adjustments were used to adjust for multiplicity. In the absence of interaction, main effects were tested; if the main effect for dose was significant, comparisons were made between 0 μM (Vehicle) and other doses using a Bonferroni adjustment. Fold differences in apoptosis were tested after a log transform using mixed models regression. Percent of cells at cell cycle levels were modeled using mixed model regression. For both apoptosis and cell cycle data, in the presence of an interaction, Bonferroni corrections were used to adjust for multiple comparisons.
